Displaying 221 - 240 of 249 results

Benign Nail Condition Linked to Rare Syndrome that Greatly Increases Cancer Risk

https://www.niams.nih.gov/newsroom/press-releases/benign-nail-condition-linked-rare-syndrome-greatly-increases-cancer-risk

Scientists at the National Institutes of Health (NIH) have discovered that the presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors of the skin, eyes, kidneys and the tissue that lines the chest and abdomen (e.g., the mesothelium).

Coping with the COVID-19 Pandemic: An update on COVID-19 Funding

https://www.niams.nih.gov/about/about-the-director/letter/coping-covid-19-pandemic-update-covid-19-funding

Dear Colleagues, When I last reached out back in April, we were all just beginning to navigate the unpredictable situation brought on by the COVID-19 pandemic. Since that time, you have all demonstrated great patience, strong resolve, and a tremendous amount of adaptability. NIH understands that the pandemic continues to upend lives and livelihoods, including those of its grantees and their institutions. To help you move through these uncertain times, the agency has provided the grantee community with a number of COVID-19 flexibilities. The agency will continue to monitor the situation and will post guide notices and updated FAQs on

Scleroderma Genomics and Health Disparities Unit Tables

https://www.niams.nih.gov/labs/scleroderma-genomics-and-health-disparities-lap/tables

« Scleroderma Genomics and Health Disparities Unit Table 1. Clinical Manifestations of scleroderma patients in the GRASP cohort (Morgan, Gourh, et al, Medicine 2017) Diffuse Scleroderma Telangiectasia Calcinosis Pulmonary ∥† Fibrosis FVC% pred † ≤70 Pulmonary ¶† Hypertension Scleroderma Renal Crisis Age at onset 0.99 (0.97-1.00) 0.99 (0.98-1.01) 1.00 (0.98-1.01)

Subset Analysis in Clinical Studies Roundtable - March 11, 2020

https://www.niams.nih.gov/about/meetings-events/roundtables/subset-analysis-clinical-studies-roundtable-march-11-2020

See participant list See Backgrounder Summary Welcome (Bob Carter, 0:00 1) Dr. Carter provided an overview of why NIAMS was holding this meeting (see background), acknowledged key staff who were involved in its development, and urged participants to keep the discussions focused on the scientific needs and opportunities related to subset analysis in clinical studies. He asked everyone to think broadly about how the various statistical approaches could be applied to NIAMS mission areas and to share their contributions during the afternoon discussion. 1 Times are noted in approximate hours and minutes on the videocast. The link does not take

Typically materials from NIAMS that are more than 5 years old will be archived.